Monday, May 15, 1995
XOMA's new strategy based on hard lessons
XOMA Corp., surveying the dashed expectations for drugs to treat endotoxin-related
diseases, is returning to the fray with a new clinical strategy that it hopes will exploit
the hard lessons from previous setbacks.
In designing the clinical trial program for its Neuprex
bactericidal/permeability-increasing protein (rBPI-21), the company is avoiding sepsis and
focusing on two key principles: targeting diseases or disorders in which the drug can be
given prophylactically or as soon as possible after the onset of symptoms; and focusing on
situations in which endotoxin-related complications are the primary problem, rather than a
secondary problem to an underlying disease.